Shigellosis or bacillary dysentery;Shigellose ou dysenterie bacillaire

Presse Medicale

Volumn 36, Issue 11 II, 2007, Pages 1606-1618

  Nicolas, Xavier ^a   Granier, Hervé ^a   Le Guen, Patrick ^b  

^a Service de Médecine Interne et Maladies Infectieuses

^b Military Teaching Hospital Clermont Tonnerre   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN;

CLINICAL FEATURE; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; EPIDEMIC; ESCHERICHIA; HAND WASHING; HUMAN; INDUSTRIALIZATION; MORTALITY; PATHOGENICITY; PERSONAL HYGIENE; PHENOTYPE; SHIGELLA; SHIGELLA BOYDII; SHIGELLA DYSENTERIAE; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLOSIS; SHORT SURVEY; SYMPTOM; WATER SUPPLY; MICROBIOLOGY; REVIEW;

DYSENTERY, BACILLARY; HUMANS;

EID: 35348903727     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2007.03.001     Document Type: Short Survey

References (88)

1. Niyogi S.K. Shigellosis. J Microbiol 43 (2005) 133-143
2. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections : implications for vaccine development and implementation of control strategies. Bull World Health Organ 77 (1999) 651-666
3. Sur D., Ramamurthy T., Deen J., and Bhattacharya S.K. Shigellosis: challenges and management issues. Indian J Med Res 120 (2004) 454-462
4. Ekdahl K., and Andersson Y. The epidemiology of travel-associated shigellosis - regional risks, seasonality and serogroups. J Infect 51 (2005) 222-229
5. Trofa A.F., Ueno-olsen H., Oiwa R., and Yoshikawa M. Dr Kiyoshi Shiga: discover of the dysentery bacillus. Clin Infect Dis 29 (1999) 1303-1306
6. Peng J., Zhang X., Yang J., Wang J., Yang E., Bin W., et al. The use of comparative genomic hybridization to characterize genome dynamics and diversity among the serotypes of Shigella. BMC Genomics 7 (2006) 218
7. Lan R., Chehani A., Donohoe K., Martinez M.B., and Reeves P.R. Molecular evolutionary relationships of enteroinvasive Escherichia coli and Shigella spp. Infect Immun 72 (2004) 5080-5088
8. Yang F., Yang J., Zhang X., Chen L., Jiang Y., Yan Y., et al. Genome dynamics and diversity of Shigella species, the etiologic agents of bacillary dysentery. Nucleic Acids Res 33 (2005) 6445-6458
9. Pupo G.M., Lan R., and Reeves P.R. Multiple independent origins of Shigella clones of Escherichia coli and convergent evolution of many of their characteristics. Proc Natl Acad Sci USA 97 (2000) 10567-10572
10. Ansaruzzaman M., Kibriya A.K.M.G., Rahman A., Neogi P.K.B., Faruque A.S.G., Rowe B., et al. Detection of provisional serovars of Shigella dysenteriae and designation as dysenteriae serotypes 14 and 15. J Clin Microbiol 33 (1995) 1423-1425
11. Donohue-Rolfe A., Acheson D.W.K., and Keusch G.T. Shiga toxin: purification, structure, and function. Rev Infect Dis 13 Suppl 4 (1991) S293-S297
12. Seidlein L.V., Kim D.R., Ali M., Lee H., Wang X.Y., Thiem V.D., et al. A multicentre study of shigella diarrhoea in six Asian countries : disease burden, clinical manifestations, and microbiology. PLoS Med 3 (2006) 1556-1569
13. Lijima Y., Oundo J.O., Taga K., Saidi S.M., and Honda T. Simultaneous outbreak due to Vibrio cholerae and shigella dysenteriae in Kenya. Lancet 345 (1994) 69-70
14. Ebright J.R., Moore E.C., Sanborn W.R., Schabert D., Kyle J., and Ishida K. Epidemic Shiga bacillus dysentery in Central America. Am J Trop Med Hyg 33 (1984) 1192-1197
15. Ries A.A., Wells J.G., Olivola D., Ntakibirora M., Nyandwi S., Ntibakivayo M., et al. Epidemic Shigella dysenteriae type 1 in Burundi : panresistance and implications for prevention. J Infect Dis 169 (1994) 1035-1041
16. Milleliri J.M. Epidémie de dysenterie bacillaire au Rwanda. Ann Soc Belg Med Trop 75 (1995) 201-210
17. Gupta A., Polyak C.S., Bishop R.D., Sobel J., and Mintz E.D. Laboratory-confirmed shigellosis in the United States, 1989-2002: epidemiologic trends and patterns. Clin Infect Dis 38 (2004) 1372-1377
18. Cicchelero V., Enard E., Géhin R., Pena L., de Valk J., and Golliot F. Cas groupés de shigellose dans l'Aude, juin 2004. BEH 18 (2006) 125-126
19. Grimont F, Grimont PAD. Les shigelloses en France : données du Centre National de référence des Escherichia coli et Shigella. http://www.invs.sante.fr/publications/2005/snmi/pdf/shigelloses.pdf.
20. Von Sonnenburg F., Tornieporth N., Waiyaki P., Lowe B., Peruski Jr. L.F., DuPont H.L., et al. Risk and aetiology of diarrhoea at various tourist destinations. Lancet 356 (2000) 133-134
21. Jiang Z.D., Lowe B., Verenkar M.P., Ashley D., Steffen R., Tornieporth N., et al. Prevalence of enteric pathogens among international travellers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis 185 (2002) 497-502
22. Ericsson C.D. Travellers' diarrhoea. Int J Antimicrob Agents 21 (2003) 116-124
23. rd, 1994. Kansenshogaku Zasshi 70 (1996) 29-41
24. Brisou P., Muzellec Y., De Jaureguiberry J.P., LeGuen P., and Yvetot J. Infections par plusieurs espèces de Shigella au retour d'Afrique. Presse Med 25 (1996) 83
25. Hyams K.C., Bourgeois A.L., Merrell B.R., Rozmajzl P., Escamilla J., Thornton S.A., et al. Diarrheal disease during Operation Desert Shield. N Engl J Med 325 (1991) 1423-1428
26. Thorntonton S.A., Sherman S.S., Farkas T., Zhong W., Torres P., and Jiang X. Gastroenteritis in US Marines during Operation Iraqi Freedom. Clin Infect Dis 40 (2005) 519-525
27. Cohen D., Sela T., Slepon R., Yavzori M., Ambar R., Orr N., et al. Prospective cohort studies of shigellosis during military field training. Eur J Clin Microbiol Infect Dis 20 (2001) 123-126
28. Wouafo N., Kemadjou C., Cunin P., Martin P.M.V., and Groupe d'Etude Salubrité du Réseau des Instituts Pasteur. Qualité hygiénique des sandwichs vendus sur la voie publique au Cameroun. Bull Liais doc OCEAC 33 (2000) 37-40
29. Levine O.S., and Levine M.M. Houseflies (Musca domestica) as mechanical vectors of shigellosis. Rev Infect Dis 13 (1991) 688-696
30. Barro N., Tidiane O.C., and Sababenedjo T.A. Carriage of bacteria by proboscises, legs, and feces of two species of flies in street food vending sites in Ouagadougou, Burkina Faso. J Food Prot 69 (2006) 2007-2010
31. Anonymous. Outbreak of Shigella flexneri and Shigella sonnei enterocolitis in men who have sex with men, Quebec, 1999 to 2001. Can Comm Dis Rep. 31 (2005) 85-90
32. Chompook P., Todd J., Wheeler J.G., Seidlein L.V., Clemens J., and Chaicumpa W. Risk factors for shigellosis in Thailand. Int J Infect Dis 10 (2006) 425-433
33. Barro N., Ouattara C.A., Nikiema P.A., Ouattara A.S., and Traore A.S. Microbial quality assessment of some street food widely consumed in Ouagadougou, Burkina Faso. Sante 12 (2002) 369-374
34. DuPont H.L., Levine M.M., Hornick R.B., and Formal S.B. Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis 159 (1989) 1126-1128
35. Nhieu G.T., and Sansonnetti P. Mechanism of Shigella entry into epithelial cells. Curr Opin Microbiol 2 (1999) 51-56
36. Sansonetti P.J. Microbes and microbial toxins : paradigm for microbial-mucosal interactions. III. Shigellosis : from symptoms to molecular pathogenesis. Am J Physiol Gastrointest Liver Physiol 280 (2001) G319-G323
37. Ogawa M., and Sasakawa C. Intracellular survival of Shigella. Cell Microbiol 8 (2006) 177-184
38. Ingersoll M.A., and Zychlinsky A. ShiA abrogates the innate T-cell response to Shigella flexneri infection. Infect Immun 74 (2006) 2317-2327
39. Le-Barillec K., Magalhaes J.G., Corcuff E., Thuizat A., Sansonetti P.J., Phalipon A., et al. Roles for T and NK cells in the innate immune response to Shigella flexneri. J Immun. 175 (2005) 1735-1740
40. Keusch G.T., Jacewicz M., Mobassaleh M., and Donohue-Rolfe A. Shiga toxin: intestinal cell receptors and pathophysiology of enterotoxic effects. Rev Infect Dis 13 Suppl 4 (1991) S304-S310
41. Bennish M.L. Potentially lethal complications of shigellosis. Rev Infect Dis 13 Suppl 4 (1991) S319-S324
42. Bennish M.L., Harris J.R., Wojtyniak B.J., and Strulens M. Death in shigellosis: incidence and risk factors in hospitalized patients. J Infect Dis 161 (1990) 500-506
43. Von Heyking A.K., and McIntosh J.J. Shigella flexneri bacteremia: an infrequently documented complication of shigellosis. Clin Microbiol News. 19 (1997) 166
44. Greenberg D., Marcu S., Melamed R., and Lifshitz M. Shigella bacteremia : a retrospective study. Clin Pediatr (Phila) 42 (2003) 411-415
45. Struelens M., Patte D., Kabir I., Salam A., Nath S.K., and Butler T. Shigella septicemia prevalence, presentation, risk factors, and outcome. J Infect Dis 152 (1985) 784-790
46. Lahat E., Aladjem M., Heipert J., and Mundel G. Shigellosis: incidence of convulsions and resistance to antibiotics. Helv Paediatr Acta 39 (1984) 123-128
47. Avital A., Maayan C., and Goitein K.J. Incidence of convulsions and encephalopathy in childhood Shigella flexneri infections. Survey of 117 hospitalized patients. Clin Pediatr. 21 (1982) 645-648
48. Gisserot O., Paris J.F., Marlier S., Carli P., and Chagnon A. Syndrome hémolytique et urémique de l'adulte au cours d'une shigellose. Med Armees 25 (1997) 183-185
49. Bennish M.L., Azad A.K., Rahman O., and Phillips R.E. Hypoglycaemia during childhood diarrhea: prevalence, pathophysiology and outcome. N Engl J Med 322 (1990) 1357-1363
50. Finch M., Rodey G., Lawrence D., and Blake P. Epidemic Reiters syndrome following an outbreak of shigellosis. Eur J Epidemiol 2 (1986) 26-30
51. Henry F.J. The epidemiologic importance of dysentery in communities. Rev Infect Dis Suppl 4 (1991) S238-S244
52. Coimbra R.S., Lenormand P., Grimont F., Bouvet P., Matsushita S., and Grimont P.A.D. Molecular and phenotypic characterization of potentially new Shigella dysenteriae serotype. J Clin Microbiol 39 (2001) 618-621
53. Houng H.S., Sethabutr O., and Echeverria P. A simple polymerase chain reaction technique to detect and differentiate Shigella and enteroinvasive Escherichia coli in human feces. Diagn Microbiol Infect Dis 28 (1997) 19-25
54. Mathan M.M., and Mathan V.I. Morphology of rectal mucosa of patients with Shigellosis. Rev Infect Dis Suppl 4 (1991) S314-S318
55. Breuil J, Armand-Lefevre L, Casin I, Dublanchet A, Collatz E. Surveillance de la sensibilité aux antibiotiques des salmonelles et shigelles isolées dans 77 hôpitaux français. BEH. 1998; 51.
56. Anonymous. Shigellosis: disease burden, epidemiology and case management. WER. 2005; 11: 94-8 (http://www.who.int/wer).
57. Anonymous. Antibiotics in the management of shigellosis. WER. 2004; 39: 355-6 (http://www.who.int/wer).
58. Bennish M.L., and Salam M.A. Rethinking options for the treatment of shigellosis. J Antimicrob Chemother 30 (1992) 243-247
59. Heikkila E., Siitonen A., Jahkola M., Fling M., Sundstrom L., and Huovinen P. Increase of trimethoprim resistance among Shigella species, 1975-1988: analysis of resistance mechanisms. J Infect Dis 161 (1990) 1242-1248
60. Munshi M.H., Sack D.A., Halder K., Ahmed Z.U., Rahaman M.M., and Murshed M.O. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet 2 (1987) 419-421
61. Biron F., Boibieux A., Tigaud S., and Peyramond D. Traitement des salmonelloses et shigelloses par les nouvelles quinolones. Pathol Biol 38 (1990) 894-898
62. Jeong Y.S., Lee J.C., Kang H.Y., Yu H.S., Lee E.Y., Choi C.H., et al. Epidemiology of nalidixic acid resistance and TEM-1 and TEM-52-mediated ampicillin resistance of shigella sonnei isolates obtained in Korea between 1980 and 2000. Antimicrob Agents Chemother 47 (2003) 3719-3723
63. Huang I.F., Chiu C.H., Wang M.H., Wu C.Y., Hsieh K.S., and Chiou C.C. Outbreak of dysentery associated with ceftriaxone-resistant Shigella sonnei : first report of plasmid-mediated CMY-26Type Amp-C β-lactamase resistance in S. sonnei. J Clin Microbiol 43 (2005) 2608-2612
64. Gordillo M.E., Singh K.V., and Murray B.E. In vitro activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother 37 (1993) 1203-1205
65. Hopkins S. Clinical safety and tolerance of azithromycin in children. J Antimicrob Chemother. 31 Suppl E (1993) 111-117
66. Khan W.A., Seas C., Dhar U., Salam M.A., and Bennish M.L. Treatment of shigellosis : V. Comparison of azithromycin and ciprofloxacin : a double-blind, randomized, controlled trial. Ann Intern Med 126 (1997) 697-703
67. Bennish M.L., Salam M.A., Khan W.A., and Khan A.M. Treatment of shigellosis: III. Comparison of one-or two dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial. Ann Intern Med 117 (1992) 727-734
68. Soares J.L., Arendt V., Coue J.C., Milleliri J.M., Philips B., Regis R., et al. Traitement court par la ciprofloxacine de la dysenterie bacillaire à Shigella dysenteriae type 1 chez des réfugiés rwandais. Med Trop. 54 (1994) 319-323
69. Salam M.A., Dhar U., Khan W.A., and Bennish M.L. Randomized comparison of ciprofloxacine suspension and pivmecillinam for childhood shigellosis. Lancet 352 (1998) 522-527
70. Zimbabwe, Bangladesh, South Africa (Zimbasa) Dysentery Study Group. Multicenter, randomized, double-blind clinical trial of short course versus standard course oral ciprofloxacin for Shigella dysenteriae type 1 dysentery in children. Pediatr Infect Dis J 21 (2002) 1136-1141
71. Eidlitz-Marcus T., Cohen Y.H., Nussinovitch M., Elian I., and Varsano I. Comparative efficacy of two- and five-day courses of ceftriaxone for treatment of severe shigellosis in children. J Pediatr 123 (1993) 822-824
72. Varsano I., Eidlitz-Marcus T., Nussinovitch M., and Elian I. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. J Pediatr 118 (1991) 627-632
73. Leibovitz E., Janco J., Piglansky L., Press J., Yagupsky P., Reinhart H., et al. Oral ciprofloxacin versus intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J 19 (2000) 1060-1067
74. Salam M.A., Seas C., Khan W.A., and Bennish M.L. Treatment of shigellosis : IV. Cefixime is ineffective in shigellosis in adults. Ann Intern Med 123 (1995) 505-508
75. Martin J.M., Piteetti R., Maffei F., Tritt J., Smail K., and Wald E.R. Treatment of shigellosis with cefixime : two days versus five days. Pediatr Infect Dis J 19 (2000) 522-526
76. Gendrel D., and Moulin F. Fluoroquinolones in paediatrics. Paediatr Drugs 3 (2001) 365-377
77. Anonymous. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. WHO 2005. http://www.who.int/topics/cholera/publications/shigellosis/fr/index.html.
78. Afssaps. Traitement antibiotique des gastro-entérites à Shigella sonnei. Presse Med 33 (2004) 1538-1545
79. Khan M.U. Interruption of shigellosis by hand washing. Trans R Soc Trop Med Hyg 76 (1982) 164-168
80. Anonymous. Future need and directions for Shigella vaccines. Background information and rationale for the meeting. WER. 2006; 6: 51-8 (http://www.who.int/wer).
81. Jennison A.V., and Verma N.K. Shigella flexneri infection: pathogenesis and vaccine development. FEMS Microbiol Rev 28 (2004) 43-58
82. Katz D.E., Coster T.S., Wolf M.K., Trespalacios F.C., Cohen D., Robins G., et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun 72 (2004) 923-930
83. Orr N., Katz D.E., Atsmon J., Radu P., Yavzori M., Halperin T., et al. Community-based safety, immunogenicity, transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun 73 (2005) 8027-8032
84. Jennison A.V., Roberts F., and Verma N.K. Construction of a multivalent vaccine strain of shigella flexneri and evaluation of serotype-specific immunity. FEMS Immunol Med Microbiol 46 (2006) 444-451
85. Oaks E.V., and Turbyfill K.R. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Vaccine 24 (2006) 2290-2301
86. Xu D., Cisar J.O., Ambulos N., Burr D., and Kopecko D.J. Molecular cloning and characterization of genes for Shigella sonnei form I O Polysaccharide : proposed biosynthetic pathway and stable expression in a live Salmonella vaccine vector. Infect Immun 70 (2002) 4414-4423
87. Rannallo R.T., Fonseka P., Cassels F., Srinivasan J., and Venkatesan M.M. Construction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608 (pCFAI) and SC608 (pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli. Infect Immun 73 (2005) 258-267
88. Barry E.M., Wang J., Wu T., Davis T., and Levine M.M. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Vaccine 24 (2006) 3727-3734